FUNDS TO VALIDATE TRANSCUTANEOUS AURICULAR NEUROSTIMULATION FOR RELIEVING WITHDRAWAL SYMPTOMS IN INFANTS BORN WITH NEONATAL ABSTINENCE SYNDROME (NAS) Dallas, TX, October 18, 2019 — Spark Biomedical, Inc., a neurostimulation device company developing solutions for opioid withdrawal, received a $217,690 SBIR grant from the National Institutes of Health HEAL initiative. The grant (1R43DA050360-01) will be used to validate the use of neurostimulation to relieve withdrawal symptoms in infants born with neonatal abstinence syndrome (NAS).

A Texas A&M University former student’s startup, Spark Biomedical, was awarded $50,000 as the winner of the 2019 Texas A&M New Ventures Competition (TNVC) hosted by the Texas A&M Engineering Experiment Station (TEES). Daniel Powell is CEO of the medical device company, which is developing noninvasive neurostimulation solutions for opioid withdrawal and addiction.

Partnership between Galen Data and Spark Biomedical strengthens their combined capability in support of connected medical devices and the ability to treat opioid withdrawal.

College Station, TX, May 3, 2019 — As Texas A&M New Ventures Competition 2019 #TNVC2019 approaches, May 15 – 17, the semi-finalist list has been announced. Spark Biomedical, Inc. is proud to be listed among the esteemed semi-finalists. Aimed at promoting the commercialization of emerging technology, the competition recognizes companies with high-growth potential and provides seed funding to help them effectively execute their ideas and advance product development.